A French national observatory of people with HIV initiating lenacapavir-based treatment after regulatory approval

Antimicrobial Agents and Chemotherapy 2026 Open access

Read full text
Authors: Charlotte Charpentier, Thomas Montrouge, Marc Wirden, Véronique Avettand-Fenoel, Camille Tumiotto, Pantxika Bellecave, Audrey Rodallec, Elisabeth Garnier, Djeneba Fofana, Sidonie Lambert-Niclot, Brigitte Montès, Marie‐Laure Chaix
+40 more Caroline Charre, Pierre Gantner, Magali Bouvier‐Alias, Enagnon Kazali Alidjinou, Pauline Coulon, Gilbert Mchantaf, Agnès Beby‐Defaux, Élodie Alessandri-Gradt, Alice Moisan, Quentin Le Hingrat, Minh Lê, Constance Delaugerre, Anne-Genevieve Marcelin, Gilles Peytavin, Vincent Calvez, Diane Descamps, the Lenacapavir Observatory Study Group, Kévin Alexandre, Clotilde Allavena, Antoine Bachelard, Fabrice Bonnet, Charles Cazanave, Violaine Esnault, Sébastien Gallien, Jade Ghosn, Laurent Hocqueloux, Christine Jacomet, Karine Lacombe, Estibalitz Lazaro, Gwenael Le Moal, Alain Makinson, Corinne Merle de Boever, Jean-Michel Molina, Bao Phung, Valérie Pourcher, Carolien Proux, Mayda Rahi, Christophe Rioux, Olivier Robineau, Axel Ursenbach
DOI: 10.1128/aac.00228-26
Cited by: 1
References: 11

Abstract

ABSTRACT There is limited data on lenacapavir (LEN) use, the newest capsid inhibitor, in observational settings. We describe population characteristics and pharmaco-virological outcomes of people with HIV-1 (PWH) who initiated LEN-based treatment. We conducted a national retrospective observational study of PWH initiating LEN-based treatment in France after its approval (December 2022). Virological failure (VF) was defined as two consecutive viral loads (VLs) ≥50 c/mL, and a non-virological response as a VL decrease of 50 c/mL at W24. Ninety-six PWH were included; 49 were virologically suppressed at initiation. Median follow-up on LEN was 12 months (IQR = 8–17). Genotypic susceptibility score was

Fields of Study & Subjects

HIV/AIDS drug development and treatment HIV Research and Treatment Virus-based gene therapy research

Publication details

Journal / source
Antimicrobial Agents and Chemotherapy
Publisher
American Society for Microbiology
Volume
70
Issue
7
Pages
e0022826–e0022826
Publication date
10 June 2026
Language
EN